Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomized single-center study

Clinical and Vaccine Immunology

Volumn 19, Issue 10, 2012, Pages 1597-1602

  Chioato, A ^a   Noseda, E ^a   Stevens, M ^b   Gaitatzis, N ^c   Kleinschmidt, A ^c   Picaud, H ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b EMStat Ltd   (United Kingdom)

^c GSK Marburg Vaccines and Diagnostics   (Germany)

^d MEDISCIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 17; MENINGOCOCCUS VACCINE; SECUKINUMAB; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HERPETIC STOMATITIS; HUMAN; HUMAN EXPERIMENT; INFLUENZA VIRUS; INJECTION SITE PAIN; MALE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OPEN STUDY; OROPHARYNX PAIN; PAIN; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCEDURAL PAIN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE DRUG DOSE; TONSILLITIS; TOOTH PAIN; TRACHEITIS; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERLEUKIN-17; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; ORTHOMYXOVIRIDAE; TH17 CELLS; YOUNG ADULT;

EID: 84867247301     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00386-12     Document Type: Article

References (10)

1. Chioato A, et al. 2010. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the IL-1 beta blocking antibody, canakinumab: Results of an open-label, parallel group, randomized, single-center study. Clin. Vaccine Immunol. 17:1952-1957.
2. Gelinck LB, et al. 2008. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67:713-716. (Pubitemid 351571939)
3. Hanania NA, et al. 2004. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J. Allergy Clin. Immunol. 113:717-724. (Pubitemid 38530429)
4. Hueber W, et al. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2:52ra72. doi:10.1126/scitranslmed.3001107.
5. Kaine JL, Kivitz AJ, Birbara C, Luo AY. 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34:272-279.
6. Lin Y, et al. 2009. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity. 31:799-810.
7. National Foundation for Infectious Diseases. 2004. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults. National Foundation for Infectious Diseases, Bethesda, MD.
8. Oren S, et al. 2008. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67:937-941. (Pubitemid 351956654)
9. Qian Y, Kang Z, Liu C, Li X. 2010. IL-17 signaling in host defense and inflammatory diseases. Cell Mol. Immunol. 7:328-333.
10. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. 2007. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res. Ther. 9:R38. doi: 10.1186/ar2174.